## Nilüfer Ertekin-Taner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9305934/publications.pdf

Version: 2024-02-01

127 papers 11,371 citations

44069 48 h-index 97 g-index

166 all docs

166
docs citations

166 times ranked 14356 citing authors

#	Article	IF	Citations
1	Epigenomic features related to microglia are associated with attenuated effect of <i>APOE</i> Îμ4 on Alzheimer's disease risk in humans. Alzheimer's and Dementia, 2022, 18, 688-699.	0.8	9
2	Alzheimer's disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. Journal of Clinical Investigation, 2022, 132, .	8.2	13
3	Clinical Deep Phenotyping of <i>ABCA7</i> Mutation Carriers. Neurology: Genetics, 2022, 8, e655.	1.9	4
4	Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans. EBioMedicine, 2022, , 103929.	6.1	2
5	Transcriptional landscape of human microglia implicates age, sex, and <i>APOE</i> â€related immunometabolic pathway perturbations. Aging Cell, 2022, 21, e13606.	6.7	23
6	Whole genome sequencing–based copy number variations reveal novel pathways and targets in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1846-1867.	0.8	13
7	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12
8	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1,1	12
9	Risk factors for severe COVID-19 differ by age for hospitalized adults. Scientific Reports, 2022, 12, 6568.	3.3	23
10	Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology. Alzheimer's and Dementia, 2021, 17, 417-430.	0.8	34
11	Plasma Biomarkers of Alzheimer's Disease in African Americans. Journal of Alzheimer's Disease, 2021, 79, 323-334.	2.6	11
12	Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC). Journal of Alzheimer's Disease, 2021, 79, 59-70.	2.6	16
13	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
14	Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. PLoS Genetics, 2021, 17, e1009224.	3.5	43
15	Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 984-1004.	0.8	25
16	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	7.7	5
17	Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105581.	1.6	7
18	Expression of an alternatively spliced variant of SORL1 in neuronal dendrites is decreased in patients with Alzheimer's disease. Acta Neuropathologica Communications, 2021, 9, 43.	5.2	7

#	Article	lF	Citations
19	Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies. PLoS ONE, 2021, 16, e0249305.	2.5	5
20	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. Nature Communications, 2021, 12, 2311.	12.8	44
21	Modulating innate immune activation states impacts the efficacy of specific $\hat{Al^2}$ immunotherapy. Molecular Neurodegeneration, 2021, 16, 32.	10.8	4
22	Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer's disease. Acta Neuropathologica Communications, 2021, 9, 93.	<b>5.</b> 2	9
23	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere–Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534.	1.1	4
24	Microglia show differential transcriptomic response to $\hat{Al^2}$ peptide aggregates ex vivo and in vivo. Life Science Alliance, 2021, 4, e202101108.	2.8	17
25	Analysis of intraoperative human brain tissue transcriptome reveals putative risk genes and altered molecular pathways in glioma-related seizures. Epilepsy Research, 2021, 173, 106618.	1.6	7
26	Apolipoprotein E regulates lipid metabolism and $\hat{l}_{\pm}$ -synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	7.7	25
27	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	3.1	11
28	Effects of sex and APOE on Parkinson's Disease-related cognitive decline. Neurologia I Neurochirurgia Polska, 2021, 55, 559-566.	1.2	6
29	Atlas of RNA editing events affecting protein expression in aged and Alzheimer's disease human brain tissue. Nature Communications, 2021, 12, 7035.	12.8	19
30	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. JAMA Neurology, 2020, 77, 225.	9.0	50
31	Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types. Cell Reports, 2020, 32, 108029.	6.4	28
32	Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. Scientific Data, 2020, 7, 340.	5.3	75
33	Deciphering cellular transcriptional alterations in Alzheimer's disease brains. Molecular Neurodegeneration, 2020, 15, 38.	10.8	42
34	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	6.4	199
35	Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	2.6	7
36	Molecular estimation of neurodegeneration pseudotime in older brains. Nature Communications, 2020, 11, 5781.	12.8	26

#	Article	IF	Citations
37	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.8	23
38	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	12.8	172
39	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	5.2	8
40	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.8	34
41	Comparative evaluation for the globin gene depletion methods for mRNA sequencing using the whole blood-derived total RNAs. BMC Genomics, 2020, 21, 890.	2.8	12
42	Epigenomic features related to microglia are associated with attenuated effect of APOE Îμ4 on Alzheimer's disease risk in humans. Alzheimer's and Dementia, 2020, 16, e043533.	0.8	2
43	<i>MAPT</i> haplotype–stratified GWAS reveals differential association for AD risk variants. Alzheimer's and Dementia, 2020, 16, 983-1002.	0.8	21
44	Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. Neuron, 2020, 107, 496-508.e6.	8.1	29
45	Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron, 2020, 106, 727-742.e6.	8.1	152
46	Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier – phenotypic variability in autosomal dominant Alzheimer's disease. Acta Neuropathologica Communications, 2020, 8, 31.	5.2	14
47	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	30.7	547
48	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	3.7	17
49	Evaluation of Associations of Alzheimer's Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures. Journal of Alzheimer's Disease, 2019, 70, 659-666.	2.6	6
50	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
51	Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight. Genome Biology, 2019, 20, 97.	8.8	122
52	Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multiâ€Ethnic (FLAME) cohort. Alzheimer's and Dementia, 2019, 15, 635-643.	0.8	29
53	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
54	The influence of $\hat{l}^2$ -amyloid on [ $<$ sup> 18 $<$ /sup> F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.1	10

#	Article	IF	Citations
55	Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants. Neurobiology of Aging, 2018, 66, 177.e7-177.e10.	3.1	1
56	[ <sup>18</sup> F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	5.3	67
57	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
58	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.8	80
59	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.8	116
60	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	10.8	75
61	Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathologica, 2018, 136, 873-885.	7.7	69
62	TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. Journal of Experimental Medicine, 2018, 215, 2247-2264.	8.5	50
63	An alternative transcript of the Alzheimer's disease risk gene SORL1 encodes a truncated receptor. Neurobiology of Aging, 2018, 71, 266.e11-266.e24.	3.1	12
64	TMEM106B haplotypes have distinct gene expression patterns in aged brain. Molecular Neurodegeneration, 2018, 13, 35.	10.8	30
65	Identification of missing variants by combining multiple analytic pipelines. BMC Bioinformatics, 2018, 19, 139.	2.6	10
66	Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 22.	6.2	27
67	Male-specific epistasis between WWC1 and TLN2 genes is associated with Alzheimer's disease. Neurobiology of Aging, 2018, 72, 188.e3-188.e12.	3.1	24
68	Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neuropathologica, 2018, 136, 709-727.	7.7	47
69	<i>APOE</i> ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.1	122
70	<i>ABCA7</i> loss-of-function variants, expression, and neurologic disease risk. Neurology: Genetics, 2017, 3, e126.	1.9	26
71	Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer's Disease Genes in African Americans Identifies Novel PSEN Variants. Journal of Alzheimer's Disease, 2017, 56, 1215-1222.	2.6	4
72	Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and Caenorhabditis elegans experiments., 2017, 13, 1133-1142.		40

#	Article	IF	Citations
73	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
74	African American exome sequencing identifies potential risk variants at Alzheimer disease loci. Neurology: Genetics, 2017, 3, e141.	1.9	25
75	A candidate regulatory variant at the <i>TREM</i> gene cluster associates with decreased Alzheimer's disease risk and increased <i>TREML1</i> and <i>TREM2</i> brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.8	48
76	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
77	Two novel loci, <i>COBL</i> and <i>SLC10A2</i> , for Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2017, 13, 119-129.	0.8	87
78	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. Genome Medicine, 2017, 9, 100.	8.2	67
79	Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Scientific Data, 2016, 3, 160089.	5.3	361
80	S4â€02â€04: Accelerating Medicines Partnership: Identifying Therapeutic Targets for Alzheimer's Disease with Comparative Transcriptomics. Alzheimer's and Dementia, 2016, 12, P322.	0.8	0
81	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
82	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	3.1	21
83	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	3.1	174
84	Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathologica, 2016, 132, 197-211.	7.7	49
85	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	3.1	69
86	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	1.9	16
87	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	2.2	30
88	Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Molecular Neurodegeneration, 2016, 11, 72.	10.8	55
89	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.8	32
90	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	3.1	23

#	Article	IF	CITATIONS
91	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.8	42
92	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
93	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
94	TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	10.8	130
95	Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurology: Genetics, 2015, 1, e15.	1.9	64
96	Role for the microtubule-associated protein tau variant p.A152T in risk of $\hat{l}_{\pm}$ -synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
97	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	9.0	39
98	Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 60-67.	3.1	90
99	Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	6.2	106
100	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
101	Late-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. Neurology, 2014, 82, 1455-1462.	1.1	51
102	Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nature Neuroscience, 2014, 17, 1156-1163.	14.8	800
103	Two rare <i>AKAP9</i> variants are associated with Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2014, 10, 609.	0.8	94
104	Genome-wide association interaction analysis for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2436-2443.	3.1	61
105	Evaluation of memory endophenotypes for association with CLU , CR1, and PICALM variants in black and white subjects. , 2014, 10, 205-213.		40
106	O3-04-01: NEXT-GENERATION RNA SEQUENCING IN ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY., 2014, 10, P214-P215.		0
107	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Molecular Neurodegeneration, 2013, 8, 19.	10.8	323
108	Other Genes Implicated in Alzheimer's Disease. , 2013, , 209-230.		0

#	Article	IF	CITATIONS
109	Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease. Current Genetic Medicine Reports, 2013, 1, 39-51.	1.9	13
110	Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E $\ddot{l}\mu$ 4, and the Risk of Late-Onset Alzheimer Disease in African Americans. JAMA - Journal of the American Medical Association, 2013, 309, 1483.	7.4	360
111	The quest for Alzheimer disease genes—focus on CSF tau. Nature Reviews Neurology, 2013, 9, 368-370.	10.1	5
112	LRRTM3 Interacts with APP and BACE1 and Has Variants Associating with Late-Onset Alzheimer's Disease (LOAD). PLoS ONE, 2013, 8, e64164.	2.5	12
113	Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants. PLoS Genetics, 2012, 8, e1002707.	3.5	225
114	Association and heterogeneity at the GAPDH locus in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 203.e25-203.e33.	3.1	17
115	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology, 2012, 79, 221-228.	1.1	144
116	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	2.1	22
117	Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Molecular Neurodegeneration, 2012, 7, 13.	10.8	75
118	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
119	Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. Molecular Neurodegeneration, 2011, 6, 31.	10.8	31
120	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	2.5	48
121	Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimer's Research and Therapy, 2010, 2, 3.	6.2	85
122	Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nature Genetics, 2009, 41, 192-198.	21.4	279
123	Genetics of Alzheimer's Disease: A Centennial Review. Neurologic Clinics, 2007, 25, 611-667.	1.8	206
124	Elevated amyloid $\hat{l}^2$ protein (A $\hat{l}^2$ 42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Human Molecular Genetics, 2005, 14, 447-460.	2.9	64
125	Genetic variants in a haplotype block spanningIDE are significantly associated with plasma A?42 levels and risk for Alzheimer disease. Human Mutation, 2004, 23, 334-342.	2.5	91
126	Fine mapping of the Â-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Human Molecular Genetics, 2003, 12, 3133-3143.	2.9	72

#	Article	lF	CITATIONS
127	Heritability of plasma amyloid ? in typical late-onset Alzheimer?s disease pedigrees. Genetic Epidemiology, 2001, 21, 19-30.	1.3	48